← Human Trials & Peer-Reviewed Studies
Effect of low-calcium and standard-calcium dialysate on serum calcium, phosphorus and full-segment parathyroid hormone in patients on peritoneal dialysis: A retrospective observational study
Plain-language guide to PMID 37877542 (2023): observational study study of Parathyroid Hormone (PTH 1-84) in 141 patients.
Key Facts
- PMID
- 37877542
- Journal
- The International journal of artificial organs
- Year
- 2023
- Study type
- Observational Study
- Authors
- An N et al. (8 authors)
- DOI
- 10.1177/03913988231206641
What This Study Did, in Plain Language
What Was Tested
Researchers studied Parathyroid Hormone (PTH 1-84) in this observational study publication.
To investigate the effects of low-calcium and standard-calcium dialysate in patients with chronic kidney disease on peritoneal dialysis, and find out which dialysate has less vascular calcification effect.
Who Took Part
The study group was 141 patients.
A total of 141 patients who had undergone peritoneal dialysis (PD) for 2 years in the PD centre from January 2012 to December 2017 were included and divided into two groups according to the calcium concentration of the PD fluid used.
Vascular calcification was assessed in patients on PD treatment.
How the Study Was Run
The timeline in the abstract includes 2 years.
The demographic characteristics and clinical information before initiation of PD were collected and compared between the two groups.
Information on the serum calcium, phosphorus and PTH, systolic and diastolic blood pressures and the use of antihypertensive and phosphate-lowering drugs in the second year of dialysis was also collected and compared between the two groups.
What Was Measured
Topics PubMed links to this paper include Calcium, Parathyroid Hormone, Dialysis Solutions, Phosphorus, Antihypertensive Agents, Renal Dialysis and Peritoneal Dialysis.
Author keywords: Chronic kidney disease, low-calcium dialysis, serum calcium, serum phosphorus and vascular calcification.
What This Means in Plain Language
This is a observational study of Parathyroid Hormone (PTH 1-84) in 141 patients over 2 years.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2023 (The International journal of artificial organs), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.